Optimind Pharma (XCNQ:OMND) Debt-to-Revenue : 5.29 (As of Nov. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Optimind Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Optimind Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.57 Mil. Optimind Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Optimind Pharma's annualized Revenue for the quarter that ended in Nov. 2023 was C$0.11 Mil. Optimind Pharma's annualized Debt-to-Revenue for the quarter that ended in Nov. 2023 was 5.29.

Optimind Pharma Debt-to-Revenue Historical Data

The historical data trend for Optimind Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optimind Pharma Debt-to-Revenue Chart

Optimind Pharma Annual Data

Trend

Feb22

Feb23

Debt-to-Revenue

N/A

3.61

Optimind Pharma Quarterly Data
	Jun21	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Debt-to-Revenue	Get a 7-Day Free Trial			2.42	3.56	3.84	5.96	5.29

Competitive Comparison of Optimind Pharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Optimind Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Optimind Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Optimind Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Optimind Pharma's Debt-to-Revenue falls into.

Optimind Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Optimind Pharma's Debt-to-Revenue for the fiscal year that ended in Feb. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.532	+	0.081)	/	0.17
	=	3.61

Optimind Pharma's annualized Debt-to-Revenue for the quarter that ended in Nov. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.571	+	0)	/	0.108
	=	5.29

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Nov. 2023) Revenue data.

Optimind Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Optimind Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Optimind Pharma (XCNQ:OMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 - 77 King Street West, TD Centre, North Tower, PO Box 95, Toronto, ON, CAN, M5K 1G8

Website

https://www.optimindpharma.com

Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities.

Optimind Pharma (XCNQ:OMND) Headlines

No Headlines